Angelini Ventures, the Pharmaceutical Group’s Corporate Venture Capital, Was Created

Angelini Industries will create and invest in startups that develop innovative solutions in the fields of biotechnology, life sciences, and digital health. The Italian multi-business group with €1.7 billion in sales and active in 21 countries with 5,800 employees, has just announced the launch of Angelini Ventures, an international venture capital firm with an endowment of €300 million, headquarters in Rome and a global team that makes up an international network of innovation experts.

The launch of the new vehicle, which will invest in Europe but also in North America and Israel, is part of Angelini Industries’ strategy aimed at promoting innovation and systemizing, financing, and implementing solutions that innovate traditional healthcare models.

Read more about Angelini Ventures and find the latest business news of the day with the Born2Invest mobile app.

Angelini Ventures, which has already planned international investments of €60 million, will focus research on brain health and market segments targeting women, children, and the elderly

The current investment portfolio includes Argobio, a Paris-based biotech ‘startup studio,’ Angelini Lumira Biosciences Fund, a North American fund that invests in startups, and Pretzel Therapeutics, a Boston-based company developing mitochondrial therapies, already funded by Eir Ventures, a Nordic VC firm focused on life sciences, and Cambridge Innovation Capital (CIC), the venture capital investor founded to improve the success rate of deeptech and life sciences at the University of Cambridge.

Angelini Industries had already focused on innovation, particularly in Indusriy 4.0, by investing in the Forward Factory accelerator launched by Cdp Venture Capital sgr. Forward Factory is based in Casalecchio di Reno and is the accelerator dedicated to startups that develop products or solutions in digital manufacturing, created together with Gellify, Digitech Fund, and seven other entities operating in the industrial and manufacturing sector, namely Comer Industries, SCM Group, Vis Hydraulics, Poggipolini, Auxiell, and Industrio Ventures, an accelerator specializing in hardware startups, and EIT Manufacturing, an ecosystem of leading European manufacturing players, as ecosystem enablers. Already in 2019, Gellify and Industrio Ventures had partnered before to create the Forward Factory program, in order to create strategies within Industry 4.0 to create new business models and increase the production capacity of plants.

Sergio Marullo di Condojanni, CEO of Angelini Industries commented, “We have been working for a long time on the creation of Angelini Ventures whose mission will be to invest internationally in high-potential ideas, opportunities, and projects that use technology to transform the future of the global healthcare ecosystem. Thanks to our specific skills and expertise, we have the ambition not only to further develop our business in the health sector but also and above all to give voice and life to solutions that have a positive impact on patients, communities, and the country system.”

Paolo Di Giorgio, CEO of Angelini Ventures added: “Angelini Ventures is a milestone in Angelini Industries’ innovation journey in healthcare. We are building a solid infrastructure to develop and invest in new ideas, collaborations, and technologies. Through Angelini Ventures, entrepreneurs will collaborate with subject matter experts who thoroughly understand the challenges of the healthcare industry and the evolving needs of patients and consumers.”

__

(Featured image by geraldoswald62 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Be Beez, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.